William Hu
胡旭波
William Hu (胡旭波) is a Managing Partner at Qiming Venture Partners, where he co-leads the firm's healthcare and life sciences investing . He's one of the firm's most visible healthcare voices — quoted on portfolio rounds spanning CAR-T therapy (Oricell Therapeutics' $70M Series C ), pulmonary hypertension devices (Pulnovo Medical's near-$100M Series C ), and AI-driven antibody design (Aureka Biotechnologies ), and he has publicly laid out his thesis on the ecosystem logic behind innovative-drug M&A . He was named to 36Kr's 2025 China equity investment industry list and the 2025 Forbes China Midas List alongside Qiming colleagues , and as of mid-2026 he remains active in that seat, including interviewing brain-computer-interface founders at Qiming's WAIC forum .
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners | WAIC Qiming Venture Partners Entrepreneurship and Investment Forum—The Evolution from Computing Power Origin to Application Success Held in Shanghai
As one of the most forward-looking and influential venture capital firms in artificial intelligence, Qiming Venture Partners has hosted this forum for four consecutive years. It is also the only forum at this year's World Artificial Intelligence Conference initiated by a venture capital firm, designed to showcase and explore the latest breakthroughs in AI's evolution from underlying computing power to industrial application — all through the lens of innovation.
Guest Lineup Revealed | 2026 WAIC Qiming Venture Partners Entrepreneurship & Investment Forum: The Evolution from Computing Power Origin to Application Deployment
Decoding the Paradigm Shift in the Large Model Era: How the Industry Can Move Beyond Pure Parameter Chasing to Ruthless Exploration of Real-World Scenarios, Cost Efficiency, and Closed-Loop Business Models
Qiming Venture Partners and Its Investors Named to 36Kr China Equity Investment Annual Lists
Time only rewards those who truly understand what they're doing.
Qiming Venture Partners' William Hu: Healthcare Investment Isn't About Hot or Cold Sectors—It's About Whether There's Enough Disruptive Potential
Someday, as China's economic and innovative strength grows, the value of Chinese entrepreneurs will naturally be reassessed.
Qiming View | William Hu: Globalization of China's Healthcare Innovation Just Beginning, Will Be Investment Theme for Next 10-20 Years
China's healthcare innovation globalization has only just begun, and it will remain a sustained investment theme for the next 10-20 years.
Qiming Headlines: Intelligence Ignites the Future — Qiming Venture Partners' 17th RMB Fund Annual Meeting and Investor Summit Successfully Held in Shanghai
Qiming Venture Partners Maintains Investment Discipline, Proactively Captures Market Opportunities as Deal Flow Continues
Qiming Venture Partners' William Hu: China Is Seeing the Birth of a Wave of Global Pharmaceutical Companies
Over the next five to ten years, more highly original R&D breakthroughs are expected to emerge from labs in China and contribute to global pharmaceutical innovation.
Qiming Venture Partners and Nearly 40 Portfolio Companies Named to VBData 2026 Future Healthcare 100
China's most authoritative and influential innovation benchmark for the healthcare industry
Qiming Venture Partners-backed precision proteomics leader Alamar Biosciences debuts on Nasdaq
Qiming Venture Partners led Alamar Biosciences' Series A round in 2020, and continued to back the company in its Series B and C rounds.
OriCell Therapeutics Announces $110 Million Pre-IPO Round, Co-Led by Qiming Venture Partners
Global leader in innovative tumor immunotherapy
Qiming Venture Partners Exclusively Leads Medway Medical's Series C Financing
a leading player in China's disposable endoscope market
Qiming Venture Partners and Its Investors Named to Diyixinsheng's 2025 China Investment Institutions and Individuals Rankings
Designed to unearth a genuine "founder's guide to fundraising, an LP's investment reference."
Qiming Venture Partners Perspective: Deepening China Healthcare Innovation to Build Global Value Core
Let China's medical innovation achievements benefit the world, and make Chinese innovation a major driving force for global healthcare development.
Morning Star | Qiming Venture Partners and Investors Honored on Touzijia 2025 Annual Equity Investment List
Recognizing investment institutions and individuals who have demonstrated sustained commitment and achieved outstanding results in the equity investment industry over the past year.
Qiming Venture Partners and Six Team Members Honored on LP CLUB 2025 Annual Rankings
Recognizing outstanding organizations and individuals who have forged ahead with remarkable achievements over the past year, setting new benchmarks for industry development.
Five AI IPOs in Seven Months, Qiming Venture Partners: Investing in AI Is the Biggest Certainty for China Over the Next Two Decades
Thirteen years, over 100 portfolio companies, covering the full AI industry chain.
Qiming Venture Partners Wins Six Awards on TMTpost 2025 Annual Pioneer List
China's venture capital market has entered a recovery channel, buoyed by the flood of AI.
Oricell Therapeutics Closes First Tranche of $70M Series C to Accelerate Global Development of Solid Tumor CAR-T Therapies
A global leader in innovative tumor immunotherapy
Qiming View | William Hu: China's Innovation Is Moving From Scattered Breakthroughs to Large-Scale, Comprehensive Advances
Over the next 5–10 years, more highly original R&D breakthroughs are expected to emerge from Chinese labs and contribute to global pharmaceutical innovation.
Qiming Venture Partners Investors Land on ChinaVenture 2025 Investor Rankings
A bellwether for China's equity investment industry and a key reference for major institutional LPs when making allocation decisions.
Qiming Venture Partners Wins Eight Awards in Zero2IPO's 2025 Rankings, Including Third Place Among China's Top VC Firms
The ranking aims to provide a robust evaluation and reference framework for China's equity investment industry.
Qiming Venture Partners Portfolio Company Insilico Medicine Successfully Lists on Hong Kong Exchanges and Clearing Limited
In 2019, Qiming Venture Partners led Insilico Medicine's Series B financing and continued to back the company through its Series C and D rounds. Prior to the IPO, Qiming Venture Partners held approximately 7% of Insilico Medicine's shares, making it one of the company's most important institutional investors.
Qiming Venture Partners' Kan Chen: Investing in Insilico Medicine four years before OpenAI went mainstream, AIDD platform has broad prospects
After completing its investment in Insilico Medicine, Qiming Venture Partners provided the company with sustained support and substantial assistance.
Qiming Venture Partners Earns Five Spots on 2025 Forbes China Midas List
Identify and recognize 100 investors who have delivered strong performance over the past five years.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 40, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Aureka Biotechnologies Closes Tens of Millions of Dollars in Series A Funding to Accelerate AI-Powered Antibody Design and Innovative Pipeline R&D
A biotech company focused on generative AI-powered antibody drug development
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 35, 2025
Staying with you through milestone moments at Qiming Venture Partners portfolio companies
AusperBio raises $63M in Series B2 funding co-led by Qiming Venture Partners
Haibo Pharmaceutical is a clinical-stage innovative drug company focused on the R&D of self-developed targeted small nucleic acid therapeutics, with "achieving clinical cure for chronic hepatitis B" as its core mission.
Qiming Venture Partners and Its Investors Named to 36Kr's 2025 China Industrial Investors Annual List
The list aims to identify investment firms and investors who embrace patience and foresight, and who are putting their convictions into practice to inject the strongest possible momentum into industries of the future.
Qiming Venture Partners' William Hu: From 'Chasing Concepts' to 'Evaluating Global Data,' China's Pharma Innovation and Investment Logic Is Being Rebuilt
Qiming Venture Partners will continue to support the development of China's innovative pharmaceutical companies, helping Chinese innovation reach the global stage — in other words, "China Innovation, Global Value."
Morning Star | Cornerstone Robotics' Guowei Ou: Committed to Full-Stack Self-Development, Aiming to Transform the Global Surgical Robotics Landscape
To succeed as a founder, you need to balance two roles: the architect and the farmer. The architect takes the high-level view, designing efficient systems and setting strategic direction for the company. The farmer puts in the steady, unglamorous work — tilling the soil day after day, staying ready for bigger opportunities when they arrive.
Morning Star | Infinigence AI's Yu Wang: Token Has Become One of the Most Core Production Factors in the Intelligence Era
Infinigence AI hopes to both empower industries across the board through AI cloud capabilities and help new smart devices reach millions of households.
Qiming Venture Partners and Portfolio Companies Win Multiple Awards at 2029 Healthcare Investment Excellence Awards
The Healthcare Investment Excellence Awards have served as an important barometer for assessing corporate market value and institutional brand influence in the healthcare investment industry. Since their inaugural release in 2017, the awards have recognized investment institutions, investors, and healthcare companies with outstanding performance and distinguished contributions each year.
Qiming Venture Partners and Executive Director Mao Shuo Named to TMTpost's 2025 H1 Pioneer Rankings
The venture capital world is flourishing in a more diverse and dynamic direction.
Qiming Venture Partners and Multiple Portfolio Companies Named to Jazzyear's 2024-2025 China Tech Industry Investment Rankings
The list aims to recognize outstanding investment institutions, investors, and science and technology innovation enterprises that have made significant contributions to the development of China's tech industry.
Dialogue | William Hu and Insilico Medicine's Ren Feng on How AI Is Driving Next-Generation Drug Discovery
For AI drug discovery companies, it's not enough to possess proprietary core technologies — they must also embed themselves deeply into the practical scenarios of pharmaceutical R&D, driving those technologies toward real-world implementation and commercial translation.
Qiming Headlines | 2025 WAIC "Qiming Venture Partners · Entrepreneurship and Investment Forum—Venture Capital Ignites the AI Technology and Application Resonance Cycle" Successfully Held
From AI 1.0 to AI 2.0, Qiming Venture Partners has invested in over 100 AI projects, with portfolio companies spanning the entire AI industry chain. The firm has helped catalyze the rise of multiple sector-defining companies and stands as one of the most active and influential investment institutions in artificial intelligence across China and Asia.
Qiming Venture Partners' Portfolio Shines with 10+ Companies on 2025 AI Cloud 100 China List
The ranking aims to identify Cloud companies that have achieved genuine commercial deployment in generative AI (GenAI) and delivered significant economic returns.
Qiming View | William Hu: China's Innovative Drug Industry Is Experiencing a Collective Breakthrough
Qiming Venture Partners' current investment focus is on driving China's innovation onto the global stage and making it an integral part of the worldwide innovation ecosystem.
Guest Lineup Revealed | Register Now for 2025 WAIC Qiming Venture Partners · Entrepreneurship and Investment Forum — Venture Capital Enters AI Technology and Application Resonance Cycle
This sub-forum will showcase and explore the latest breakthroughs in AI technology and applications through the lens of innovation. Qiming Venture Partners will bring together leading scholars and top entrepreneurs in the field — from both the startup and investment perspectives — for four keynote speeches and four panel discussions.
Dialogue | Building Surgical Robots at the 'Tip of the Pyramid'
The R&D of surgical robots demands high standards and presents significant technical challenges. Cornerstone Robotics has built a foundation of safety and stability through independent R&D and a high degree of domestic sourcing, with outstanding clinical trial results demonstrating that its products have reached world-class levels.
Qiming Venture Partners Portfolio Companies Shine on 2025 China Globalization Rising Stars 100 List
The ranking focuses on companies that achieved at least $10 million in overseas revenue in 2024, as well as companies that have already generated overseas revenue to date and possess strategic deployment capabilities in the global market.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 24, 2025
Following Qiming Venture Partners' portfolio companies and their milestone moments with you
Qiming Star | Infinigence AI's Yu Wang: Exploring the Next Frontier of Edge Intelligence
The future of edge intelligence requires a two-way commitment between academia and industry. Only when hardware innovation and algorithmic breakthroughs form a closed loop can we truly unlock AI's potential to transform the physical world.
Qiming Venture Partners Portfolio Company WeRide's W5 Driverless Logistics Vehicle Approved for Road Testing Across Guangzhou's Huangpu District
This marks WeRide's second citywide autonomous-driving permit in Guangzhou for its W5 unmanned delivery vehicle, following the road-testing license obtained in Nansha District this April. The steadily expanding operational footprint is accelerating the company's push toward scaled commercialization of driverless logistics vehicles.
Qiming Venture Partners' Duane Kuang, William Hu, and Alex Zhou Named to PEDaily's 2025 TOP100 Investors List
The awards have been held for ten consecutive editions, becoming a window into observing industry shifts, with the aim of selecting 100 outstanding investors who have delivered strong investment performance while also driving progress in China's venture capital landscape.
Qiming Perspective | William Hu on the Ecosystem Logic Behind Innovative Drug M&A Integration
In this era of transformation, Qiming Venture Partners places greater emphasis on whether a company's technology and products achieve genuine breakthroughs, and whether it can deliver clinical value that others cannot. Qiming Venture Partners supports enterprises that bring tangible benefits to patients.
Qiming Venture Partners and Its Investors Named to 36Kr's 2025 China Equity Investment Industry Lists
Investment firms focused on technological innovation are well-positioned to stand out in this wave of industrial upgrading.
Qiming Venture Partners' 16th RMB Fund Annual Meeting and Investor Summit Successfully Held in Shanghai
China's high-quality companies have reached a valuation level that's become genuinely attractive.
Qiming Venture Partners and Over 10 Portfolio Companies Named to 2024 China Healthcare Industry Investment Glory List
The list not only recognizes outstanding investment institutions, investors, and companies, but also provides directional guidance for the evolution of industry investment logic, redefines the value standards for talent, and brings positive momentum to the industrial ecosystem.
Qiming Venture Partners and 50+ portfolio companies named to 2025 Future Healthcare 100 list
These rankings and reports aim to document the year's industry breakthroughs and reveal the growth patterns of listed companies and evolving industry trends, offering a reference for healthcare enterprises and entrepreneurs.
Qiming Star | Ark Biosciences Announces Latest Research Results for First RSV-Specific Antiviral Drug Ziresovir Published in The Lancet Child & Adolescent Health | Bilingual
This study, the world's first Phase 3 clinical trial covering RSV-infected infants under six months of age, successfully fills the evidence gap for targeted treatment approaches in this high-risk population and provides critical evidence for building a comprehensive RSV disease management system.
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 07, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Morning Star | Pulnovo Medical Raises Nearly $100 Million in Series C, Co-Led by Qiming Venture Partners | Bilingual
This round was oversubscribed twice, making it the largest market-driven financing in the Asia-Pacific innovative medical device sector in recent years.
What Would Qiming Venture Partners Look Like Without Nisa Leung?
Together, we welcome a new era.
Qiming Venture Partners Raises Record 6.5 Billion RMB; Duane Kuang: Scale Was Not the Goal
2020 was a watershed year.
"6th Future Healthcare 100" Roundtable: Investing in Future Healthcare — How to Nurture World-Class Innovative Enterprises?
VBData's "6th Future Healthcare 100 Conference" took "China Story" as its theme. During the heavyweight panel discussion, titled *Investing in Future Healthcare: How to Support the Emergence of World-Class Innovative Companies*, six investment firms gathered to debate how China can continue producing world-class innovators and lead at the global frontier.
MaHui | Source Code Capital's Xingchen Zhang Named to Cyzone's 40 Under 40 Investors List
"Finding tech founders full of conviction"
